NATCO announces launch of Carboplatin Injection (generic of Paraplatin) in the U.S. market
A new generic carboplatin injection is entering the U.S. market, increasing supply of this chemotherapy drug.
Source →The trace
How it reaches your house.
Starting from Generic Oncology Injectable Vials (Cisplatin, Carboplatin, Paclitaxel), we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Cancer and specialty drugs →supply upGeneric Oncology Injectable Vials (Cisplatin, Carboplatin, Paclitaxel)
NATCO's U.S. launch adds a new generic carboplatin supplier, increasing availability across the generic oncology injectable vial family that includes carboplatin products.
87% confidenceCisplatin / carboplatin API →supply upA new carboplatin injection adds supply to a critical oncology drug class, easing availability for downstream cancer and specialty drugs.
86% confidenceGeneric Oncology Injectable Vials (Cisplatin, Carboplatin, Paclitaxel) →supply up
Where it lands
What you buy, and what you own.
Goods you buy
Cancer and specialty drugs
Companies you may own
No named companies on this path.
Tap a company to see what it told the SEC could break it.
In the MyPRIA app, this is checked against your own holdings.